Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma

Imagem de Miniatura
Arquivos
art_SOUZA_Different_morphology_stage_and_treatment_affect_immune_cell_2012.PDF (1.15 MB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
ATANAZIO, Marcelo Junqueira
Citação
HISTOPATHOLOGY, v.61, n.4, p.587-596, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims: Development of effective immune-based therapies for patients with non-small-cell lung carcinoma (NSCLC) depends on an accurate characterization of complex interactions that occur between immune cells and the tumour environment. Methods and results: Innate and adaptive immune responses were evaluated in relation to prognosis in 65 patients with surgically excised NSCLC. Immunohistochemistry and morphometry were used to determine the abundance and distribution of immune cells. We found low numbers of immune cells and levels of cytokines in the tumour environment when compared with surrounding parenchyma. Smoking was associated inversely with the adaptive immune response and directly with innate immunity. We observed a prominent adaptive immune response in squamous cell carcinomas (SCC) but greater innate immune responses in adenocarcinomas and large cell carcinomas. Cox model analysis showed a low risk of death for smoking <41 packs/year, N-0 tambour stage, squamous carcinoma, CD4(+) > 16.81% and macrophages/monocytes >4.5%. Collectively, the data indicate that in NSCLC there is not a substantive local immune cell infiltrate within the tumour. Conclusion: Although immune cell infiltration is limited in NSCLC it appears to have an impact on prognosis and this may be of relevance for new immunotherapeutic approaches.
Palavras-chave
cytokines, immune cells, interleukins, lung cancer
URI
https://observatorio.fm.usp.br/handle/OPI/926
Referências
  1. Aloysius MM, 2006, SURG-J R COLL SURG E, V4, P195
  2. Al-Shibli K, 2009, HISTOPATHOLOGY, V55, P301, DOI 10.1111/j.1365-2559.2009.03379.x
  3. Antonangelo L, 1997, CHEST, V111, P110, DOI 10.1378/chest.111.1.110
  4. Arenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603
  5. Baleeiro RB, 2008, CANCER IMMUNOL IMMUN, V57, P1335, DOI 10.1007/s00262-008-0468-7
  6. Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
  7. BARBUTO JAM, 1995, CANCER IMMUNOL IMMUN, V40, P31, DOI 10.1007/BF01517233
  8. Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417
  9. BERNARDI FD, 1995, CHEST, V107, P614
  10. Bernardi FD, 1997, MODERN PATHOL, V10, P992
  11. Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
  12. Brambilla E, 2004, PATHOLOGY GENETICS T
  13. Carvalho HA, 1997, HISTOPATHOLOGY, V31, P420, DOI 10.1046/j.1365-2559.1997.2940885.x
  14. Chan CW, 2008, CELL DEATH DIFFER, V15, P58, DOI 10.1038/sj.cdd.4402235
  15. Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352
  16. Chaux P, 1996, LAB INVEST, V74, P975
  17. Coca S, 1997, CANCER, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
  18. Coventry BJ, 2003, BRIT J CANCER, V89, P533, DOI 10.1038/sj.bjc.6601114
  19. de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
  20. Dimitriadou V, 1997, ANTICANCER RES, V17, P1541
  21. DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135
  22. Fricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429
  23. Gong Xuanju, 2000, Zhonghua Zhongliu Zazhi, V22, P135
  24. Gordon SB, 2002, BRIT MED BULL, V61, P45, DOI 10.1093/bmb/61.1.45
  25. Green RM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006860
  26. Ishigami S, 2000, CANCER, V88, P577, DOI 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
  27. Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915
  28. Kataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317
  29. Matheus RS, 2004, PATHOL RES PRACT, V200, P13, DOI 10.1016/j.prp.2003.12.007
  30. META M, 1995, CANCER IMMUNOL IMMUN, V40, P235, DOI 10.1007/BF01519897
  31. Minamoto H, 2003, HISTOPATHOLOGY, V43, P427, DOI 10.1046/j.1365-2559.2003.01704.x
  32. Moriya K, 2010, CANCER IMMUNOL IMMUN, V59, P1083, DOI 10.1007/s00262-010-0835-z
  33. Neves AR, 2005, CANCER IMMUNOL IMMUN, V54, P61, DOI 10.1007/s00262-004-0550-8
  34. O'Mahony D, 2005, J CLIN ONCOL, V23, P1
  35. Parra ER, 2008, HISTOL HISTOPATHOL, V23, P987
  36. Porta C, 2007, ANTICANCER RES, V27, P165
  37. Rodrigues OR, 1997, JPN J CLIN ONCOL, V27, P298, DOI 10.1093/jjco/27.5.298
  38. Saito DMS, 2007, HISTOPATHOLOGY, V50, P525, DOI 10.1111/j.1365-2559.2007.02623.x
  39. Sallusto P, 1994, J EXP MED, V179, P1109
  40. Sandel MH, 2005, CLIN CANCER RES, V11, P2576, DOI 10.1158/1078-0432.CCR-04-1448
  41. Schrump D, 2005, CANC PRINCIPLES PRAC, P753
  42. Souza P, 2010, HUM PATHOL, V41, P239, DOI 10.1016/j.humpath.2009.07.018
  43. TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849
  44. Takanami I, 2001, J THORAC CARDIOV SUR, V121, P1058, DOI 10.1067/2001.113026
  45. Tataroglu C, 2004, LUNG CANCER-J IASLC, V43, P47, DOI 10.1016/j.lungcan.2003.08.013
  46. Vermaelen KY, 2001, J EXP MED, V193, P51
  47. Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6
  48. Weibel ER, 1990, MODELS LUNG DIS MICR, P199
  49. Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910
  50. Wu J, 2003, ADV CANCER RES, V90, P127, DOI 10.1016/S0065-230X(03)90004-2
  51. ZHOU LJ, 1992, J IMMUNOL, V149, P735
  52. Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC